Link Cell Therapies was launched by Stanford founders Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital to tackle one of the greatest challenges in cancer cell therapy – the development of safe and effective CAR T agents for patients with solid tumors.
Our unique logic-gate technology enables a new level of precision required for the safe deployment of CAR T beyond current indications. Link’s AND-gate CAR Ts require co-expression of cancer targets to drive cell cytotoxicity, thereby providing greater specificity for tumor than what has been achieved to date with existing logic-gate technologies. Combined with additional platforms under development, we are advancing a suite of exciting therapeutic programs that promise to unlock the potential of CAR T therapy across multiple, important cancer indications including solid tumors and certain hematologic cancers.
